Propolis shows antimicrobial activity but suffers from poor solubility, and stability. • Key gut pathogens (H. pylori, F. nucleatum, C. difficile) worsen GI disorders. • Increasing antimicrobial resistance underscores the need for alternative therapeutic approaches. • SLNs represent a promising strategy to improve propolis delivery and therapeutic potential in GI conditions.
Propolis-loaded solid lipid nanoparticles targeting H. pylori associated with gastro-intestinal diseases
Robuffo, Iole;
2026
Abstract
Propolis shows antimicrobial activity but suffers from poor solubility, and stability. • Key gut pathogens (H. pylori, F. nucleatum, C. difficile) worsen GI disorders. • Increasing antimicrobial resistance underscores the need for alternative therapeutic approaches. • SLNs represent a promising strategy to improve propolis delivery and therapeutic potential in GI conditions.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
